Ginkgo Bioworks and XWELL Implement Expanded CDC Traveler-based Genomic Surveillance Program to Test for More than 30 Known Pathogens

The program can be an effective early warning system for public health and national security officials, leveraging voluntary nasal and wastewater sampling from international travelers at major U.S. airports BOSTON, Nov. 6, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: LIC Source Type: news